UFPT Quote, Financials, Valuation and Earnings

Repligen has a net margin of 11.37% compared to UFP Technologies's net margin of -20.22%. UFP Technologies's return on equity of 18.87% beat Repligen's return on equity of -1.29%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 81%. On the other hand Repligen has an analysts' consensus of $194.07 which suggests that it could grow by 33.7%. Given that UFP Technologies has higher upside potential than Repligen, analysts believe UFP Technologies is more attractive than Repligen.

UFP Technologies has a beta of 1.147, which suggesting that the stock is 14.692% more volatile than S&P 500. In comparison Repligen has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5.001%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are smaller than Repligen quarterly revenues of $167.5M. UFP Technologies's net income of $16.4M is higher than Repligen's net income of -$33.9M. Notably, UFP Technologies's price-to-earnings ratio is 27.70x while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 12.87x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of 11.37% compared to UFP Technologies's net margin of -1226.82%. UFP Technologies's return on equity of 18.87% beat VolitionRX's return on equity of --.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 81%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 513.33%. Given that VolitionRX has higher upside potential than UFP Technologies, analysts believe VolitionRX is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.147, which suggesting that the stock is 14.692% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are larger than VolitionRX quarterly revenues of $474.5K. UFP Technologies's net income of $16.4M is higher than VolitionRX's net income of -$5.8M. Notably, UFP Technologies's price-to-earnings ratio is 27.70x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 35.50x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of 11.37% compared to UFP Technologies's net margin of -4291.67%. UFP Technologies's return on equity of 18.87% beat Catheter Precision's return on equity of -65.84%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 81%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 376.19%. Given that Catheter Precision has higher upside potential than UFP Technologies, analysts believe Catheter Precision is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.147, which suggesting that the stock is 14.692% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are larger than Catheter Precision quarterly revenues of $96K. UFP Technologies's net income of $16.4M is higher than Catheter Precision's net income of -$4.1M. Notably, UFP Technologies's price-to-earnings ratio is 27.70x while Catheter Precision's PE ratio is 0.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 1.12x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 11.37% compared to UFP Technologies's net margin of -10.04%. UFP Technologies's return on equity of 18.87% beat Xtant Medical Holdings's return on equity of -35.34%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 81%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 224.07%. Given that Xtant Medical Holdings has higher upside potential than UFP Technologies, analysts believe Xtant Medical Holdings is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.147, which suggesting that the stock is 14.692% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. UFP Technologies's net income of $16.4M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, UFP Technologies's price-to-earnings ratio is 27.70x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 0.62x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.